Fintel reports that on July 11, 2025, Cantor Fitzgerald initiated coverage of Tvardi Therapeutics (NasdaqCM:TVRD) with a Overweight recommendation.

Analyst Price Forecast Suggests 96.77% Upside

As of June 20, 2025, the average one-year price target for Tvardi Therapeutics is $54.01/share. The forecasts range from a low of $37.09 to a high of $81.90. The average price target represents an increase of 96.77% from its latest reported closing price of $27.45 / share.

See our leaderboard of companies with the largest price target upside.

The projected annual non-GAAP EPS is -0.79.

What is the Fund Sentiment?

There are 2 funds or institutions reporting positions in Tvardi Therapeutics. This is an increase of 1 owner(s) or 100.00% in the last quarter. The put/call ratio of TVRD is 0.01, indicating a bullish outlook.

What are Other Shareholders Doing?

SUNAMERICA SERIES TRUST - SA Legg Mason Tactical Opportunities Portfolio Class 1 holds 0K shares representing 0.00% ownership of the company.